SCHEMBL24035877

SCHEMBL24035877

COC(=O)c1cnn(C2COC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 2/20 0.44
▸ ACHE P22303 3/20 0.41
▸ EIF4E P06730 1/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.39
▸ TLR8 Q9NR97 1/20 0.39
▸ TLR7 Q9NYK1 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ LRRK2 Q5S007 3/20 0.38
▸ PSMB8 P28062 1/20 0.38
▸ PSMB9 P28065 1/20 0.38
▸ MAP3K5 Q99683 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ MGLL Q99685 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ OGA O60502 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24035837 0.89 ROCK1 (0.48) ROCK1ACHEMKNK1MKNK2LRRK2
SCHEMBL17162236 0.86 ACHE (0.51) ACHEPSMB8PSMB9ALDH1A1HPGD
SCHEMBL24036427 0.85 ROCK1 (0.46) ROCK1ACHELRRK2PSMB8PSMB9
SCHEMBL12803550 0.84 OGA (0.48) ROCK1ACHEEIF4EMKNK1MKNK2
SCHEMBL24035880 0.83 ACHE (0.60) ACHELRRK2PSMB8PSMB9ALDH1A1
SCHEMBL3766078 0.82 ACHE (0.58) ACHELRRK2PSMB8PSMB9ALDH1A1
SCHEMBL24035776 0.80 MPO (0.56) ROCK1ACHEPSMB8PSMB9ALDH1A1
SCHEMBL27411719 0.80 MKNK1 (0.46) ROCK1ACHEEIF4EMKNK1MKNK2
SCHEMBL22411770 0.79 GSK3B (0.47) ROCK1ACHEPSMB8PSMB9PIM1
SCHEMBL24035852 0.79 DYRK1A (0.48) ACHEPSMB8PSMB9OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
CN-116710430-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2023-09-05 — — CN disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 — — US disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS ROCK1 1855/4885ACHE 4265/4885EIF4E 3329/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS ROCK1 1855/4885ACHE 4265/4885EIF4E 3329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback